Bailey Perrin Bailey - A Registered Limited Liability Partnership - 1-866-716-8300

Zyprexa

Bailey Perrin Bailey LLP is no longer accepting Zyprexa cases.

(Zyprexa is also commonly misspelled as “Zyprixa, Zyprexia, Zyphrexa, Zypexa, and Ziprexa.”)

If you would like to see the letter that the manufacturers sent doctors about new warnings.

Zyprexa is used to treat schizophrenia and bipolar disorder.

Zyprexa is linked to weight gain, diabetes, glucose problems, increased cholesterol, and increased triglycerides.

In a recent National Institute of Mental Health study, some disturbing facts about weight gain and Zyprexa were found:

Patients taking Zyprexa gained an average of 2 pounds per month.

30% of Zyprexa recipients gained 7% or more of their original weight during the study. Only 12% of the patients using the first-generation drug experienced a similar weight gain.

31% of Zyprexa recipients found the weight gain or metabolic effects so distressing that they chose to stop treatment, compared with a mere 3% of patients who discontinued a first generation drug for similar reasons.

As reported by the FDA in January of 2004:

FDA and Lilly notified healthcare professionals of revision to the WARNINGS section of labeling, describing the increased risk of hyperglycemia and diabetes in patients taking Zyprexa. FDA has asked all manufacturers of atypical antipsychotic medications, including Lilly, to add this Warning statement to labeling.

If you are suffering from any of the following conditions after taking this drug, you may want to contact us for more information:

• Diabetes
• Ketoacidosis
• Severe weight gain
• Diabetic coma
• Heart attack
• Hyperglycemia
• Neuroleptic Malignant Syndrome
• Pancreatitis
• Stroke
• Tardive Dyskinesia
• Seizures
• Gynecomastia